Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Zai Lab Limited

< Previous 1 2 Next >
Zai Lab Announces Participation in Investor Conference in January 2025
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
Zai Lab Announces the Inclusion of AUGTYRO® (repotrectinib) for ROS1+ NSCLC and Other Updates in China’s National Reimbursement Drug List
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
Zai Lab Announces Anticipated Closing of Public Offering of American Depositary Shares and Full Exercise of Underwriters' Option to Purchase Additional American Depositary Shares
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
Zai Lab Announces Pricing of Public Offering of American Depositary Shares
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
Zai Lab Announces Proposed Public Offering of American Depositary Shares
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
Zai Lab Announces Third Quarter 2024 Financial Results and Recent Corporate Updates
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
Zai Lab and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China
From Zai Lab Limited
Via Business Wire
Tickers ARGX ZLAB
Zai Lab Reports Positive Topline Data from Phase 3 Bridging Trial Evaluating KarXT for the Treatment of Schizophrenia in China
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
ZL-1310, an Investigational DLL3-Targeted Antibody-Drug Conjugate (ADC), Demonstrates Promising Objective Response Rates and Safety Profile in Extensive-Stage Small Cell Lung Cancer
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
Zai Lab Announces Participation in November and December Investor Conferences
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
Zai Lab to Host Webcast Presentation to Discuss Data from Early Clinical Program Evaluating Its Investigational DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
Zai Lab to Announce Third Quarter 2024 Financial Results and Recent Corporate Updates on November 12, 2024
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
Zai Lab to Present Data from Phase 1 Trial of ZL-1310, Its Investigational Antibody-Drug Conjugate (ADC) for DLL3+ Solid Tumors, at EORTC-NCI-AACR Symposium (ENA) 2024
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
Zai Lab to Present Preclinical Data of ZL-1503, an IL-13/IL-31 Bispecific Antibody for the Treatment of Atopic Dermatitis, at EADV Congress 2024
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
Zai Lab to Present Preliminary Data From Phase 1 Trial of ZL-1218, an Investigational Anti-CCR8 Antibody for the Treatment of Advanced Solid Tumors, at ESMO Congress 2024
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
Zai Lab Announces Participation in September Investor Conferences
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
Zai Lab Announces Second Quarter 2024 Financial Results and Recent Corporate Updates
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
Zai Lab and argenx Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China
From Zai Lab Limited
Via Business Wire
Tickers ARGX ZLAB
Zai Lab-Supported Study Published in Cell Provides New Insights with Potential to Improve Treatment of HRD-Positive Ovarian Cancers, Including Through Combination PARP Inhibitor and CCR8 Therapy
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
Zai Lab to Announce Second Quarter 2024 Financial Results and Recent Corporate Updates on August 6, 2024
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
Zai Lab Announces Dr. Harald Reinhart to Retire as Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases; Dr. Rafael Amado to be Appointed President, Head of Global R&D
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
Zai Lab Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
Zai Lab Announces Participation in May and June Investor Conferences
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
Zai Lab Announces Acceptance of Supplemental Biologics License Application with Priority Review for Efgartigimod Alfa Injection (Subcutaneous Injection) in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
Zai Lab Announces Approval of AUGTYRO™ (repotrectinib) for Patients with ROS1-positive NSCLC by China’s NMPA
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
Zai Lab Announces First Quarter 2024 Financial Results and Recent Corporate Updates
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
Zai Lab to Announce First Quarter 2024 Financial Results and Recent Corporate Updates on May 8, 2024
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
Zai Lab Statement on Executive Management Team’s Agreement on Share Activities
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
Zai Lab Presentations at AACR 2024 Annual Meeting to Showcase Ongoing Clinical Studies in Key Global Oncology Programs
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.